Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA).

Journal article

BACKGROUND: Boosted protease inhibitor (bPI) monotherapy (bPImono) potentially has substantial cost, safety and operational benefits. It has never been evaluated as second-line antiretroviral therapy (ART) in Africa. METHODS: After 24 weeks of lopinavir/ritonavir-containing second-line therapy, DART participants were randomized to remain on combination therapy (CT), or change to bPImono maintenance (SARA trial; ISRCTN53817258). Joint primary end points were CD4(+) T-cell changes 24 weeks late...

Expand abstract

Authors: Gilks, C; Walker, A; Dunn, D; Gibb, D; Kikaire, B

• Publication status: Published
• Journal: Antiviral therapy
• Volume: 17
• Issue: 7
• Pages: 1363-1373
• Publication date: 2012-01-01
• DOI: 10.3851/imp2253
• EISSN: 2040-2058
• ISSN: 1359-6535
• Language: English
• Keywords: Treatment Outcome; Female; Humans; DART Virology Group and Trial Team; Drug Therapy, Combination; RNA, Viral; Mutation; CD4 Lymphocyte Count; Drug Resistance, Viral; Africa; Middle Aged; Adult; Male; Viral Load; Ritonavir; Time Factors; Viremia; HIV Infections; HIV; HIV Protease Inhibitors; Lopinavir